SCHEMBL29818587

SCHEMBL29818587

Cn1nnc(-c2ncc(N=C(c3ccccc3)c3ccccc3)cc2Cl)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM2B Q8NHM5 1/20 0.36
▸ KDM4C Q9H3R0 1/20 0.36
▸ PDGFRB P09619 1/20 0.35
▸ FGFR1 P11362 1/20 0.35
▸ KDR P35968 1/20 0.35
▸ SMN1; SMN2 Q16637 3/20 0.33
▸ TSHR P16473 1/20 0.33
▸ PDK2 Q15119 1/20 0.33
▸ ESR1 P03372 2/20 0.32
▸ ESR2 Q92731 2/20 0.32
▸ NPC1 O15118 2/20 0.32
▸ RAB9A P51151 2/20 0.32
▸ CASP3 P42574 1/20 0.32
▸ SENP8 Q96LD8 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ AXL P30530 1/20 0.32
▸ MGAM O43451 1/20 0.32
▸ AMY1A P0DUB6 1/20 0.32
▸ GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25417390 1.00 KDM2B (0.36) KDM2BKDM4CPDGFRBFGFR1KDR
SCHEMBL25418401 0.80 HIF1A (0.36) SMN1; SMN2TSHRESR1ESR2RAB9A
SCHEMBL29818528 0.80 HIF1A (0.36) SMN1; SMN2TSHRESR1ESR2RAB9A
SCHEMBL29818457 0.79 DRD2 (0.34) —
SCHEMBL25418293 0.79 DRD2 (0.34) —
SCHEMBL25206827 0.71 EPHX2 (0.39) KDM2BKDM4C
SCHEMBL25212088 0.71 BDKRB1 (0.35) KDM2BKDM4C
SCHEMBL27020067 0.70 ESR1 (0.37) SMN1; SMN2ESR1ESR2GAAALDH1A1
SCHEMBL29818445 0.70 DRD4 (0.34) —
SCHEMBL25419864 0.70 DRD4 (0.34) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4284804-A1 TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS Schrödinger, Inc. (US) 2023-12-06 — — EP disclosed
CN-117120442-A Tricyclic compounds useful for treating cancer, autoimmune disorders, and inflammatory disorders 薛定谔公司 2023-11-24 — — CN disclosed
WO-2022164789-A9 TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS SCHRÖDINGER, INC. (US) 2023-05-25 — — WO disclosed
WO-2022164789-A1 TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISODERS SCHRÖDINGER, INC. (US) 2022-08-04 — — WO disclosed
Send feedback